Advances in immune checkpoint inhibitor-induced cardiotoxicity
Immune checkpoint inhibitors(ICIs)have emerged as one of the novel immunotherapy drugs in recent years,and been approved for the treatment of multiple tumour types.However,over-activation of the immune system may lead to immune-related advese events,among these,ICIs-induced cardiotoxicity include myocarditis,pericardial disease,atherosclerosis and vasculitis.Although ICIs-induced cardiotoxicity is rare,it may lead to serious clinical complications and even death.Thus,timely identification and management of ICIs-induced cardiotoxicity is vital in clinical practice.Once diagnosed,prompt treatment is required according to the severity of the disease.Standardized prevention and treatment strategies need multidisciplinary collaboration to provide long-term individualized monitoring and management for patients.
万方数据
维普
